...
首页> 外文期刊>Cytokine >Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-??B-mediated inflammatory genes expression
【24h】

Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-??B-mediated inflammatory genes expression

机译:黄芪甲苷IV通过抑制NF-κB介导的炎症基因表达改善链脲佐菌素诱导的糖尿病大鼠的肾脏损伤

获取原文
获取原文并翻译 | 示例
           

摘要

Accumulating evidence suggests that inflammatory processes are involved in the development of diabetic nephropathy (DN). However, there are no effective interventions for inflammation in the diabetic kidneys. Here, we tested the hypothesis that Astragaloside IV(AS-IV), a novel saponin purified from Astragalus membranaceus (Fisch) Bge, ameliorates DN in streptozotocin (STZ)-induced diabetic rats through anti-inflammatory mechanisms. Diabetes was induced with STZ (65mg/kg) by intraperitoneal injection in rats. Two weeks after STZ injection, rats were divided into three groups (n=8/each group), namely, diabetic rats, diabetic rats treated with AS-IV at 5 and 10mgkg-1d-1, p.o., for 8weeks. The normal rats were chosen as nondiabetic control group (n=8). The rats were sacrificed 10weeks after induction of diabetes. AS-IV ameliorated albuminuria, renal histopathology and podocyte foot process effacement in diabetic rats. Renal NF-??B activity, as wells as protein and mRNA expression were increased in diabetic kidneys, accompanied by an increase in mRNA expression and protein content of TNF-??, MCP-1 and ICAM-1 in kidney tissues. The ??1-chain type IV collagen mRNA was elevated in the kidneys of diabetic rats. All of these abnormalities were partially restored by AS-IV. AS-IV also decreased the serum levels of TNF-??, MCP-1 and ICAM-1 in diabetic rats. These findings suggest that AS-IV, a novel anti-inflammatory agent, attenuated DN in rats through inhibiting NF-??B mediated inflammatory genes expression. ? 2013 Elsevier Ltd.
机译:越来越多的证据表明,炎症过程与糖尿病性肾病(DN)的发展有关。然而,没有有效的干预措施来治疗糖尿病肾。在这里,我们测试了一种假设,即黄芪甲苷IV(AS-IV)是一种从黄芪(Fisch)Bge纯化的新型皂苷,可通过抗炎机制改善链脲佐菌素(STZ)诱导的糖尿病大鼠中的DN。大鼠腹腔注射STZ(65mg / kg)可诱发糖尿病。注射STZ后两周,将大鼠分为三组(n = 8 /每组),即糖尿病大鼠,分别以5和10mgkg-1d-1的p.o.口服AS-IV治疗8周。选择正常大鼠作为非糖尿病对照组(n = 8)。诱导糖尿病10周后处死大鼠。 AS-IV改善了糖尿病大鼠的蛋白尿,肾脏组织病理学和足细胞足突消失。糖尿病肾中肾NF-κB活性以及蛋白质和mRNA表达增加,同时肾组织中TNF-α,MCP-1和ICAM-1的mRNA表达和蛋白质含量增加。在糖尿病大鼠的肾脏中,α1-链IV型胶原mRNA升高。所有这些异常都被AS-IV部分修复。 AS-IV还降低了糖尿病大鼠的血清TNF-α,MCP-1和ICAM-1水平。这些发现表明,新型的抗炎药AS-IV通过抑制NF-κB介导的炎性基因表达而减弱了大鼠的DN。 ? 2013爱思唯尔有限公司

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号